Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
Status:
Not yet recruiting
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
Determine the safety and recommended Phase II dose of olaparib in combination with
17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.